Vasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference
Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.
- Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.
- Vasomune’s lead drug candidate AV-001, codeveloped with AnGes Inc, is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor.
- Activation of the Tie2 receptor plays a critical role in promoting vascular stability, barrier integrity and endothelial quiescence.
- “Vasomune is grateful to the National Research Council Canada for grant #IRAP-965762 which supported the Phase 1 study.